Understanding and managing malaria drug resistance
Preparing for a world with artemisinin resistance: using individual-based epidemiological modeling to minimize the long-term detrimental effects of antimalarial drug resistance
This study is looking at how to stop the spread of drug-resistant malaria, especially in young children in Africa, by using computer models to understand how these tough strains develop, so we can keep effective treatments available for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10888189 on NIH RePORTER |
What this research studies
This research focuses on the malaria parasite Plasmodium falciparum, which is particularly deadly for children under five in Africa. It aims to develop strategies to prevent and slow the spread of drug-resistant strains of malaria, especially artemisinin-resistant genotypes. By using advanced computer modeling techniques, the researchers will simulate how these drug-resistant strains evolve and spread in human populations, allowing for better management of malaria treatment. The goal is to ensure that effective antimalarial drugs remain available and effective for future generations.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of five living in regions of Africa where malaria is prevalent.
Not a fit: Patients who are not affected by malaria or those living outside of the targeted regions in Africa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing malaria treatment, ultimately reducing the incidence and mortality of malaria in vulnerable populations.
How similar studies have performed: Previous research has shown success in managing malaria through drug combination therapies, but this specific approach to modeling drug resistance is innovative and aims to address emerging challenges.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Boni, Maciej F — Temple Univ of the Commonwealth
- Study coordinator: Boni, Maciej F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.